$LEXX – Lexaria’s GLP-1 Human Study Reaches Full Enrollment Lexaria Bioscience ($LEXX) announced that its GLP-1-H26-7 human study has reached full enrollment, with dosing continuing on schedule. The study is evaluating Lexaria’s DehydraTECH-semaglutide oral formulations, including tablets and capsules, with a focus on drug absorption, safety and tolerability. The study also includes a comparison with $NVO’s Wegovy tablet. Dosing is expected to conclude around mid-November 2026, followed by analysis and reporting of the results. Positive findings could support further development of Lexaria’s oral drug-delivery technology and potential pharmaceutical partnerships. However, the study has not yet established that Lexaria’s formulations are more effective than existing treatments. In short: $LEXX has completed enrollment in its GLP-1 human study and continues dosing on schedule, with results expected after the dosing phase concludes. #LEXX #Biotech #GLP1 #Semaglutide #ClinicalTrials